This is a Phase 3 Study for PRIMARY PROGRESSIVE MS Patients, aged 18-55, who are still ambulatory (can be with cane or walker). Ocrelizumab is a drug similar to rituximab that depletes circulating B cells. It is a humanized monoclonal against CD20 which is expressed only on B cells. In an earlier study, rituximab (a chimeric monoclonal antibody against CD20) showed much promise in the subset of younger PPMS patients [Hawker et al. Ann Neurol. 66:460-71, 2009].
2/3 of enrolled subjects will receive active ocrelizumab, and 1/3rd will receive placebo.
Inclusion Criteria: PPMS still able to walk (can be with assistance), aged 55 or younger.
Length of Trial: 2.5 years, with open-label extension.
WHO IS THE PRINCIPAL INVESTIGATOR?
Anne H. Cross, MD
660 South Euclid Avenue
Campus Box 8111
Saint Louis, MO 63110
Susan Fox, Clinical Coordinator
We will need medical records documenting diagnosis of MS, MRI reports, CSF results (if done).
Fax to attention of Susan Fox at 314-747-1345
Location of Trial: John L. Trotter MS Center
Washington University School of Medicine
517 S. Euclid
St. Louis, MO 63110
Clinical Trial Sponsor: